bpc-157 for healing denver Rapid Release BPC-157 - LeadWest Medical

European Journal of Pharmacology, 869 , 172891

Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 12 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each Subcutaneous doses are much smaller than oral doses because of injection volume limits and because direct subQ absorption skips the gut

TB-500s key mechanisms include: Actin sequestration: By binding G-actin (monomeric actin), TB-500 keeps it available for cell migration and wound repair rather than polymerizing prematurely into structural filaments